Biotech psychedelics company BetterLife Pharma Inc. (OTCQB: BETRF) in collaboration with the Carleton University Dept.
June 29, 12:41 PM
Canadian life sciences company Nirvana Life Sciences Inc. (CSE: NIRV), focused on research & development of non-addictive pain management and relapse prevention products for pain and addictions, has been granted approval to build its R&D facility in Vancouver by Canada’s governmental department of Health.
June 28, 3:29 PM
Two publicly traded psychedelics companies announced supply agreements. HAVN Life Sciences (OTC: HAVLF) will provide mental health clinic MPB Group Inc. with psilocybin-containing mushrooms for its therapeutic retreats in Jamaica and Optimi Health Corp.
Meet Alvaro Torres, CEO Of Lat Am & UK’s Top Medical Marijuana Brand At Benzinga’s Cannabis Capital Conference In September
June 28, 11:25 AM
After a prosperous Miami event this past April, the Benzinga Cannabis Capital Conference will take place in Chicago on September 13-14. As always, the meeting will host leading executives and investors who will talk about the industry’s present and future.
Cybin’s Psilocybin Analog CYB003 Gets FDA Clearance For Trial To Potentially Treat Major Depressive Disorder
June 28, 8:15 AM
Psychedelic biopharma company Cybin Inc. (NEO: CYBN) has received FDA Investigational New Drug Application (IND) approval for a Phase 1/2a clinical trial evaluating its proprietary CYB003 for treating major depressive disorder (MDD).
June 24, 3:24 PM
Pharmala Biotech Holdings Inc. (CSE: MDMA), a company focused on research, development and manufacturing of MDMA and similar class molecules, has registered a trademark for its clinical-grade, Good Manufacturing Practice MDMA product, to be available as “Laneo MDMA.”
DMT Therapy Developer Small Pharma Posts Financial Results, Reaffirms Potential Of Short-Acting Psychedelics
June 23, 6:48 PM
Biotech company Small Pharma Inc. (OTCQB: DMTTF), producer of short-acting psychedelic-assisted therapies for diverse mental health conditions, announced its financial results earlier this month for the fiscal year ended Feb. 28, 2022.
June 22, 3:52 PM
Cybin Inc. (NEO: CYBN) (NYSE American: CYBN), a biopharma company focused on progressing “psychedelics to therapeutics” through proprietary drug discovery platforms announced its financial and business results ended March 31, 2022.